Mechanism
- GLP-1 / GIP-GLP-1: incretin receptor agonism — slows gastric emptying, increases satiety, improves insulin secretion.
- Metabolic surgery: anatomical and hormonal changes that alter gut signaling and appetite regulation independent of ongoing medication.
Evidence base
- GLP-1: STEP and SURMOUNT programs — meaningful weight and A1c reduction while treatment continues.
- Surgery: STAMPEDE, Mingrone, SOS — durable A1c improvement and long-term mortality benefit in selected patients.
Durability
- GLP-1: Benefit is largely lost on discontinuation (STEP-4, SURMOUNT-4).
- Surgery: Benefit persists years after the procedure; some remission can be lost over time and requires monitoring.
Risk profile
- GLP-1: GI side effects, pancreatitis risk (rare), muscle-mass loss concerns, injection burden.
- Surgery: Anesthesia, bleeding, leak, stricture, nutritional deficiency, small long-term risks.
Cost
- GLP-1: Ongoing monthly cost for as long as the medication is used.
- Surgery: Higher one-time cost; no ongoing medication cost specific to the procedure.
Combining, sequencing, or switching
For some patients, GLP-1 therapy is used first and continued; for others, it is a bridge; for a subset, surgery is added after a plateau. Sequencing is a physician-guided decision. Never stop prescribed medication without the prescribing physician.
Ready for an individualized evaluation?
A physician evaluation is the only way to determine candidacy. Outcomes vary; no result is guaranteed.